Welcome to this UK AstraZeneca produced and funded website

This website is intended for UK Healthcare Professionals only.

 

The website contains both promotional and non-promotional content.

 

If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk

 

For any other UK residents please visit astrazeneca.co.uk

This website is intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk

Home-page-hero-image.png

ACT NOW: CHALLENGE EXPECTATIONS

IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER TREATMENT

LYNPARZA (olaparib) monotherapy and in combination with abiraterone and prednisone
or prednisolone are the first PARP inhibitor therapy options for metastatic castration-resistant prostate cancer (mCRPC) recommended by NICE and accepted by the SMC1-4


LYNPARZA combination therapy for mCRPC

NICE recommended and SMC accepted for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated1,2

 

LYNPARZA tablets are indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated.5

DISCOVER LYNPARZA COMBINATION THERAPY
Two older men standing side by side both looking at the camera Two older men standing side by side both looking at the camera
Portrait of an older man looking serious Portrait of an older man looking serious


LYNPARZA monotherapy for BRCAm mCRPC

NICE recommended and SMC accepted for treating hormone-relapsed mCRPC with BRCA1/2-mutations that has progressed after NHA (such as abirateronezor enzalutamide) in adults3,4

 

LYNPARZA tablets are indicated as monotherapy for the treatment of adult patients with mCRPC and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy, including an NHA.5

DISCOVER LYNPARZA MONOTHERAPY

Discover useful information for managing LYNPARZA
treatment in your patients

There is a range of resources readily available to support you in prescribing
LYNPARZA to patients with mCRPC

LEARN MORE

 

Please refer to the SmPC for further information to minimise the risks associated with the use of the medicine before making any prescribing decisions.

Want to learn more about LYNPARZA?

BRCA1/2m=BRCA1/2 mutation; mCRPC=metastatic castration-resistant prostate cancer; MoA=mode of action; NHA=new hormonal agent; NICE=National Institute for Health and Care Excellence; PARP=poly (ADP-ribose) polymerase; SMC=Scottish Medicines Consortium.

 

  1. Olaparib with abiraterone for untreated hormone relapsed metastatic prostate cancer. NICE TA951. February 2024. Available at https://www.nice.org.uk/guidance/ta951/resources/olaparib-with-abiraterone-for-untreated-hormonerelapsed-metastatic-prostate-cancer-pdf-82615723963333. Accessed January 2026.
  2. Scottish Medicines Consortium. Olaparib (Lynparza). March 2024. Available at: https://www.scottishmedicines.org.uk/medicines-advice/olaparib-lynparza-mcrpc-full-smc2617/. Accessed January 2026.
  3. Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer. May 2023. https://www.nice.org.uk/guidance/ta887/resources/olaparib-for-previously-treated-brca-mutationpositive-hormonerelapsed-metastatic-prostate-cancer-pdf-82613738657221. Accessed January 2026.
  4. Scottish Medicines Consortium, SMC2366. Olaparib (Lynparza). October 2021. https://www.scottishmedicines.org.uk/media/6338/olaparib-lynparza-final-september-2021-for-website.pdf. Accessed January 2026.
  5. LYNPARZA (olaparib). Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/9488/ smpc#about-medicine. Accessed January 2026.

GB-73791 | DOP: February 2026

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling ‌‌‌0‌‌‌8‌‌‌‌‌0‌‌‌‌0‌‌‌ ‌‌7‌‌‌‌‌‌8‌‌‌3‌‌‌ ‌‌0‌‌‌‌‌0‌‌‌‌3‌‌‌‌3‌‌‌.

Welcome to this UK AstraZeneca produced and funded website

This website is intended for UK Healthcare Professionals only.

 

The website contains both promotional and non-promotional content.

 

If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk

 

For any other UK residents please visit astrazeneca.co.uk

These Lynparza website pages were funded and produced by AstraZeneca UK and MSD UK.

 

This website is intended for UK Healthcare Professionals only.


The website contains both promotional and non-promotional content.


If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk


For any other UK residents please visit astrazeneca.co.uk

Enhance your knowledge, stay informed

Be the first to know. Hear about events, products and ways to support your patients.

GB-74216| DOP : February 2026